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Background. The eﬀect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is
still ill deﬁned. Methods. We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized
to at least 3-year blinded ACEi with trandolapril (2mg/day) or non-ACEi therapy who had preproliferative or proliferative
retinopathy at baseline. Results. Over a median (interquartile range) follow-up period of 35.8 (12.4–60.7) months, retinopathy
regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi
therapy (adjusted for predeﬁned baseline covariates HR (95% CI): 2.75 (1.18–6.42), P = .0193). Concomitant treatment with
or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably aﬀect the incidence of retinopathy
regression. Conclusions. Unlike ndCCB, ACEi therapy may have an additional eﬀect to that of intensiﬁed BP and metabolic control
in promoting regression of diabetic retinopathy.
1.Introduction
Despite the beneﬁcial eﬀects of photocoagulation, retinopa-
thy remains the leading cause of blindness in people aged
30 to 69 years, that ultimately aﬀects more than 60% of
type 2 diabetics [1]. Duration of diabetes, poor metabolic
control, and arterial hypertension have been associated with
the development and progression of retinopathy, although
their relative role appears to diﬀer in diﬀerent series and
clinical conditions [1, 2]. Undoubtedly, strict metabolic
control is essential for the prevention and treatment of
retinopathy. Reducing Blood Pressure (BP), however, has
been recognized as an additional, and probably even more
eﬀective, therapeutic intervention [2].
However, the speciﬁc eﬀects on the retina of diﬀerent




has been never formally compared with other agents such
asnon-dihydropyridinecalciumchannelblockers(ndCCBs).
Moreover, no study primarily addressed whether regression
of retinopathy can be achieved in those who already have
retinal involvement.
To formally explore these issues, we took advantage of
a large cohort of hypertensive type 2 diabetics from the
BErgamo Nephrologic Diabetes Complications Trial (BENE-
DICT) [3]. These patients were expected to have a high2 Journal of Ophthalmology
prevalence of retinopathy at study entry because of the
concomitance of two strong and possibly synergistic risk
factors, arterial hypertension and type 2 diabetes. They were
randomized to receive at least 3 years of treatment with the
ACEi trandolapril, the nondihydropyridine CCB (ndCCB)
verapamil, their combination (VeraTran), or placebo plus
other antihypertensive drugs titrated to a systolic/diastolic
BP goal of 120/80mmHg or less. Data showed that patients
on ACEi therapy (either as trandolapril alone or the
combination VeraTran) compared to those on non-ACEi
therapy (verapamil or placebo) had a signiﬁcantly lower
incidence of persistent microalbuminuria, which is an early
marker of diabetic nephropathy and a major risk factor for
cardiovascular disease in this population.
T h ep r i m a r ya i mo ft h ep r e s e n ts t u d yw a st oe v a l u a t e
whether, in type 2 diabetic patients, treatment with the ACEi
trandolapril may promote regression of diabetic retinopathy
more eﬀectively than antihypertensive medications that do
notdirectlyinterferewithangiotensinIIproductionoractiv-
ity, at comparable BP and metabolic control. Secondarily, we
compared the eﬀects of trandolapril and non-RAS inhibitor
therapy on newly onset retinopathy in those patients with-
out evidence of retinal involvement at study entry. The
results of the analyses formed the basis of the present
report.
2. Methods
2.1. Patients and Study Design. This study is a pre-speciﬁed
analysis of data from the BENEDICT trial. Study design
and patient characteristics have been described in detail
elsewhere [3]. Brieﬂy, BENEDICT was a prospective, ran-
domized, double blind, parallel group study that evaluated
the possibility of preventing the onset of persistent microal-
buminuria in 1209 patients with type 2 diabetes (WHO
criteria), arterial hypertension (systolic or diastolic BP more
than 130 or 85mmHg, or concomitant antihypertensive
therapy),andnormalUrinaryAlbuminExcretion(UAE)rate
(UAE < 20μg/min in at least 2 of 3 consecutive overnight
urine collections) randomly assigned to at least 3 years
of treatment with one of the following study drugs: I, a
ndCCB: verapamil SR, 240mg/day; II, an ACEi: trandolapril
2mg/day; III, the ﬁxed-dose combination of verapamil SR,
180mg/day plus trandolapril 2mg/day: VeraTran; and IV,
placebo. The target BP after randomization and throughout
the whole study period was to be less than 120/80mmHg for
all the treatment groups. Other antihypertensive drugs (with
the exception of RAS inhibitors and ndCCBs diﬀerent from
thestudydrugs)couldbeusedtoachieveandmaintaintarget
BP according to predeﬁned guidelines.
The analysis was primarily aimed at evaluating the
rate of regression of diabetic retinopathy in patients with
retinal involvement at study entry considered as a whole
and, then, according to their original randomization to
RAS-inhibitor or non-RAS inhibitor therapy (Figure 1).
Secondarily, the study compared the eﬀect of RAS and non-
RAS inhibitor therapy on newly onset retinopathy in those
without evidence of retinal involvement at inclusion. Finally,
for explorative purposes only, patients were considered
according to their randomization to one of the four original
treatment arms.
The study protocol was in accordance with the decla-
ration of Helsinki and was approved by the institutional
review board at each Center and by the Safety Committee
of the BENEDICT study. All patients gave written informed
consent.
2.2. Retinal Evaluation. Retinal evaluations by ophthal-
moscopyandphotography(inasubgroup)werescheduledat
baseline, every year thereafter, and at ﬁnal visit in all patients
included in the BENEDICT trial who had been randomized
attheClinicalResearchCenter(CRC)“AldoandCeleDacc` o”
of The Mario Negri Institute and at the Unit of Diabetology
of the Azienda Ospedaliera “Ospedali Riuniti di Bergamo”.
They were referred to the Unit of Ophthalmology of the
Azienda Ospedaliera where they were evaluated indepen-
dently by two ophthalmologists (I. I. AND M. F.) blinded
to the clinical and laboratory data of the patients. The
diagnoses were compared for consistency. Patients with an
inconsistent diagnosis were evaluated by a third independent
ophthalmologist (S.T.), and his diagnosis was recorded as
ﬁnalandconsideredfordataanalyses[5].Aftermydriasiswas
induced, indirect binocular ophthalmoscopy was performed
by a L-0185 slit-lamp biomicroscope (magniﬁcation 10x and
16x) and handheld lens (magniﬁcation 90x). Photographs
of four standard 30◦ ﬁelds of each eye were taken through
dilated pupils in stereo pairs (lateral to macula, macula, disc,
and nasal) with Canon CF 60UV fundus camera (Tokio,
Japan) [4]. The pictures were printed on Kodak Ektachrome
100-colour slide ﬁlm. Photographs were initially assessed
for quality and adherence to the protocol. Inadequate
photographs were discharged.
The eye with the most severe involvement was used
for categorization of retinal involvement. Pre-proliferative
retinopathy was deﬁned by the presence of microaneurysms,
hemorrhages,hardexudates,venouscongestion,cottonwool
spots, or intraretinal microvascular abnormalities. Prolif-
erative retinopathy was diagnosed when new vessels, glial
proliferation, preretinal hemorrhage, vitreous hemorrhage,
scars of photocoagulation (known to have been directed at
new vessels), and/or retinal detachment were found. Patients
withnoneoftheseabnormalitieswereclassiﬁedasnothaving
retinopathy [5, 6]. Based on this simpliﬁed classiﬁcation,
regression of retinopathy was deﬁned as a persistent (up to
the ﬁnal visit) change in the stage of retinal involvement
from proliferative to pre-proliferative retinopathy, or from
pre-proliferative retinopathy to no retinal involvement.
2.3. BP and Other Outcome Variables. Trough systolic and
diastolic (Korotkoﬀ phase I/V) BPs were measured in the
morning before treatment administration by use of an
appropriate cuﬀ with a sphygmomanometer and with the
patient in a sitting position after at least 5 minutes rest.
Three measurements to the nearest 2mmHg were obtained,
two minutes apart at each time point, and the average
of the three measurements was recorded for statistical
analyses. Mean arterial pressure (MAP) was calculated asJournal of Ophthalmology 3
diastolic BP plus one third of the pulse pressure. All the
laboratory measurements were centralized at the Laboratory
of the CRC. HbA1C was measured by ion exchange high-
performance liquid chromatography and urinary albumin
excretion rate by nephelometry.
Data were reported in dedicated case record forms and
doubly entered in an ad hoc database that was eventually
merged with the BENEDICT database. Before analyses, all
data were monitored by the Monitoring Unit of the CRC.
2.4. Sample Size. Regression of retinopathy was the primary
outcome variable of a substudy ancillary to BENEDICT
phase A. At the time the present analyses were planned,
no data were available on the regression of retinopathy in
hypertensive patients with type 2 diabetes on intensiﬁed BP
and metabolic control, as well as on a possible additional
eﬀect on disease regression of ACEi therapy. Thus, it was
impossible to establish ap r i o r ithe sample size required to
provide the analyses with an adequate power to detect the
hypothesized treatment eﬀect on retinopathy. Actually, this
wasanexplorativestudyperformedinallconsentingpatients
with available ophthalmologic evaluations.
2.5. Statistical Analyses. The analyses were performed by
the Laboratory of Biostatistics of the CRC. Patients were
eligible if they had a funduscopy evaluation at baseline.
Main outcome variable was regression of retinal changes in
patients with retinopathy at study entry. Secondary outcome
variable was newly onset retinopathy in those with no
retinal changes at study entry. In the primary outcome
analyses, patients with retinopathy were considered as a
whole regardless of the stage of retinal involvement. For
outcome analyses, systolic and diastolic BP measurements
were included separately in the model. Continuous variables
were compared by unpaired t-test or Wilcoxon Rank Sum
tests and categorical variables by χ2 test or Fisher’s Exact
test. Regression of retinopathy was evaluated by means of
Cox regression models in order to obtain the hazard ratio
(HR) and its 95 percent conﬁdence interval. Patients without
funduscopy evaluation on follow up were conventionally
classiﬁed as having one day of follow up and without the
event of interest. Unless otherwise stated, statistical analyses
were done according to the intention-to-treat principle and
considered adjustments according to pre-deﬁned baseline
covariates (site, age, smoking status, diastolic BP, and log-
transformed urinary albumin excretion). All the statistical
analyses were performed using SAS version 9 (SAS Institute
Inc, Cary, NC). A P-value of less than .05 was considered as
statistically signiﬁcant. No P-value adjustment was carried
out for multiple comparisons. Data are expressed as mean
± standard deviation (SD) or median and interquartile (IQ)
range or percentages.
3. Results
3.1. Baseline Characteristics. Of the 1209 patients random-
ized in the original BENEDICT cohort, 583 patients were
referredtothetwocentersinvolvedinthepresentstudy.Five-
hundred-ﬁfty patients had a baseline funduscopy evaluation
(Figure 1). Patients with funduscopy evaluation, compared
to those without, had a lower body mass index, poorer
metabolic control and higher BP at baseline (Table 1). Four-
hundred-sixty patients (83.6%) had no evidence of retinal
involvement. Of the remaining 90 patients with funduscopy
data, 82 had a pre-proliferative and 8 had a proliferative
form of retinopathy. All had BP and HbA1C data at baseline
and on follow-up and were therefore available for this
analysis. Compared to patients without evidence of retinal
involvement, those with retinopathy (either pre-proliferative
or proliferative) at inclusion reported a signiﬁcantly longer
duration of diabetes, were more hypertensive and had
signiﬁcantly higher HbA1C, blood glucose levels, and uri-
nary albumin excretion (Table 1). Age, gender distribution,
smoking habit, serum creatinine, and lipid proﬁle were
similar between groups. A similar proportion of patients
with retinopathy were on ACEL or non-ACEi therapy, and
a similar proportion of patients were on ndCCB or non-
ndCCB therapy (Table 1). Baseline characteristics of patients
on ACEL or non-ACEi therapy, as well as of patients on
ndCCB or non-ndCCB therapy were comparable, with the
only exception of systolic BP that was lower in those on
ndCCBcomparedtothoseonnon-ndCCBtherapy(Table1).
The proportion of patients on concomitant medications
at baseline and on follow-up was also similar within each
considered treatment group, with the only exception of the
proportion of patients on ﬁbrate therapy at baseline that was
lowerinthendCCBthaninthenon-ndCCBtreatmentgroup
(Table 2).
3.2. Regression of Diabetic Retinopathy According to ACEi,
or Non-ACEi Therapy. Over a median (IQ range) follow-
up period of 35.8 (12.4–60.7) months, retinal changes
regressed in 27 of 90 patients (30.0%) who had retinopathy
at study entry. Regression was observed in 18 of the 42
patients (42.9%) randomized to ACEi therapy and in 9 of
the 48 patients (18.8%) randomized to non-ACEi therapy
(Figure 2) (HR (95% CI): 2.62 (1.17–5.84), P = .0188,
(unadjusted) and 2.75 (1.18–6.42), P = .0193 (adjusted for
predeﬁned baseline covariates)) (Figure 3(a)). Systolic and
diastolic BP were similar in the two treatment groups at
baseline(Table1)andatdiﬀerentvisitsonfollow-up.HbA1C
was also similar between groups at baseline (Table 1)a n do n
followup.Theregressionrateofretinopathywassigniﬁcantly
diﬀerent even after adjustment for baseline and follow-up
systolic/diastolic BP and HbA1C and for systolic/diastolic
BP and HbA1C changes versus baseline (P<. 05 for all
considered adjusted Hazard Ratios).
3.3. Regression of Diabetic Retinopathy According to ndCCB
or Non-ndCCB Therapy. Regression of retinopathy was
observed in 12 of the 50 patients (24.0%) randomized
to ndCCB therapy and in 15 of the 40 patients (37.5%)
randomized to non ndCCB therapy (HR (95% CI): 0.64
( 0 . 3 0t o1 . 3 7 ) ,P = .25 (unadjusted) and 0.56 (0.25 to
1.25), P = .16 (adjusted for predeﬁned baseline covariates))
(Figure3(b)).SystolicBPwaslowerinthendCCBthaninthe
non-ndCCB group at baseline (Table 1), but the diﬀerence
progressively weaned on subsequent follow up visits, while4 Journal of Ophthalmology
1209 randomized
to BENEDICT phase A
659 baseline fundus not available
(326 assigned to non ACEi, 333 assigned to ACEi)
550 with available fundus at
baseline
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Figure 2: Fundus photographs showing pre-proliferative changes (a) at baseline in a patient who had a regression of eye lesions after three
yearsoftrandolapriltherapy(b).Thispictureprovidesacomprehensiveexampleofthreetypicallesions,microaneurysms(MA),hemorrages
(E), and hard exudates (HE, that may regress in type 2 diabetic patients on ACE inhibitor therapy combined to intensiﬁed metabolic and
blood pressure control, as in the BENEDICT trial.
diastolic BP was similar in the two treatment groups at
baseline (Table 1)a sw e l la sa td i ﬀerent visits on follow-up.
HbA1C was similar between groups at baseline (Table 1)a n d
at diﬀerent visits on follow up.
3.4. Regression of Diabetic Retinopathy According to the Origi-
nal Treatment Arm. Regression of retinopathy was observed
in 10 (52.6%), 8 (34.8%), 2 (7.4%), and 5 (23.8%) of the 19,
23,27,and21patientsrandomizedtotrandolapril,VeraTran,
verapamil, or placebo, respectively. The HR (95% CI) for
trandolapril, VeraTran, or verapamil versus placebo was,
respectively: 2.47 (0.84–7.23), P = .10; 1.72 (0.55–5.32), P =
.35; 0.61 (0.16–2.27), P = .46 (unadjusted) and: 2.61 (0.84–
8.13), P = .10; 1.89 (0.53–6.71), P = .33; and 0.91 (0.19–
4.33), P = .90 (adjusted for predeﬁned baseline covariates.)
Systolic and diastolic BP and HbA1C were not signiﬁcantly
diﬀerentbetweentreatmentgroupsbothatbaseline(Table1)
and on follow-up (data not shown).
3.5. Newly Onset Diabetic Retinopathy. Retinal changes
developed in 61 of 460 patients (13.3%) who had no
evidence of diabetic retinopathy at study entry. Newly onset
retinopathy was observed in 33 of the 229 patients (14.4%)
randomized to RAS inhibitor therapy and in 28 of the 231
patients (12.1%) randomized to non-RAS inhibitor therapy
(unadjusted: HR (95% CI) 0.968 (0.582–1.610), P = .90;
adjusted for predeﬁned baseline covariates: HR (95% CI)
0.984 (0.588–1.646), P = .95). No signiﬁcant diﬀerence
between groups was detected even after adjustment for pre-
deﬁned baseline and follow up covariates, including baseline
and follow up BP and HbA1 C (data not shown). No








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































∗Adjusted for predeﬁned baseline characteristics
(b)
Figure 3: Cumulative incidence of patients with retinal involve-
ment at baseline who achieved regression of diabetic retinopathy
according to randomization to ACEi therapy YES or NO (a) or to
ndCCB therapy YES or NO (b).
patients on ndCCB and non-ndCCB therapy (data not
shown).
4. Discussion
Our study shows that regression of diabetic retinopathy is
possible in a substantial proportion of hypertensive patients
with type 2 diabetes and tight BP and metabolic control.
Importantly, we found that therapy with antihypertensive
drugs that directly interfere with the RAS, such as the
ACEi trandolapril, is more eﬀective in inducing regression
than non-RAS inhibiting therapy, while treatment regimens
includingornotincludingthendCCBverapamilhavesimilar
eﬀects. Secondarily, data showed that the protective eﬀect of
trandolapril against diabetic retinopathy is not appreciably
enhanced by combined therapy with verapamil, and the
eﬀect of verapamil is not diﬀerent from that of placebo. On
the other hand, trandolapril as well as verapamil had no spe-
ciﬁc protective eﬀect against the development of retinopathy
in patients with no evidence of retinal involvement at study
entry.
These ﬁndings are in line with the recent DIRECT-
Protect 2 trial showing that the angiotensin receptor blocker
(ARB) candesartan increases regression of retinopathy by
34% over placebo in type 2 diabetic patients with mild
to moderately severe retinal lesions but has no appreciable
eﬀectonprogressionofretinopathyinthosepatientswithout
retinal involvement at inclusion [7].
Hypertension may increase the shear stress on the vascu-
lar wall, leading to hyperplasia of the vascular endothelium
and to hypertrophia of its cytoskeleton [8]. This process may
be magniﬁed in the diabetic retina, since defective autoregu-
lation may favor the transmission of high systemic BP down
to the microcirculation, causing capillary hypertension and
structural damage to the endothelium [9]. Thus, lowering
BP might decrease the barotrauma to the vascular wall and
therefore prevent or regress the microvascular changes of the
diabetic retina.
Throughout the observation period the regression rate
of diabetic retinopathy was more than double in patients on
trandolapril than in controls. This ﬁnding was not explained
by blood pressure control that was similar across diﬀerent
treatmentgroupsandwasconsistentwithaspeciﬁcbeneﬁcial
eﬀect of trandolapril on the retina.
Activation of the RAS has been involved in defective
autoregulation of the retinal microvasculature, and inhibi-
tion of the RAS may therefore explain the improved perfu-
sion observed during ACE inhibition therapy. Moreover, the
hemodynamic eﬀects of RAS inhibition have been suggested
to contribute to the partial regression of retinal changes
observed during ACEi therapy in hypertensive rats with
streptozotocin induced diabetes [10].
ACE inhibitors, however, may also interfere with a series
ofnonhemodynamiceﬀectsmediatedbytheRAS.TheRASis
involvedingrowthfactorexpression,inparticularofvascular
endothelial growth factor (VEGF) and tumor growth factor
(TGF)-beta. Increased VEGF expression in the diabetic rat
is normalized by ACE inhibition, which eventually translates
into an amelioration of retinal injury. In the presence of high
glucose, angiotensin II stimulates TGF-beta secretion, which
increases matrix accumulation by activating the synthesis
of collagen I and ﬁbronectin and by decreasing matrix
degradation [11]. Consistently, blockade of angiotensin II
synthesis by ACEi decreases the expression of TGF-beta,
reduces the accumulation of matrix protein synthesis, and
accelerates its degradation.
Finally, ACEi may interfere with RAS-independent
metabolic pathways. By inhibiting bradykinin degradation,
they may increase the bioavailability of nitric oxide and
prostacyclin which, through an increased bioavailability and
activity of Na+,K +-ATPase in the vasculature of the diabetic
retina, might contribute to the functional improvement
detected by electroretinography [12] during ACEi therapy.
Finding that trandolapril was not protective against the
development of retinopathy conﬁrms and extends data from8 Journal of Ophthalmology
DIRECT-Protect 2 trial that the angiotensin II receptor
blockercandesartanhadnoappreciableeﬀectonprogression
of retinopathy in type 2 diabetic patients without retinal
involvement at inclusion [7]. A possible explanation is that
all patients were on intensiﬁed BP and metabolic con-
trol, which substantially decreased the overall incidence of
events,reducingthestatisticalpowerofcomparativeanalyses
between treatment groups. Indeed, while optimized BP and
metabolic control increased the number of regressions in
those with retinal involvement at baseline, which increased
the power of comparative analyses between treatment
groups, in those without retinal disease optimized treatment
decreased the incidence of newly onset retinopathy, which
decreased the statistical power of between-group compar-
isons. An alternative or complementary explanation would
be that mechanisms sustaining progression of retinopathy
maydiﬀerfromthoseatthebasisofdiseaseregression,which
might translate into diﬀerent response to ACEi therapy of
patients with or without retinal changes to start with.
On the other hand, present data on the retina, combined
with the results of the BENEDICT Phase 1 study showing
that, in patients with type 2 diabetes and normal urinary
albumin excretion, verapamil therapy failed to prevent
microalbuminuria [3], conﬁrm that this drug has no speciﬁc
protective eﬀects against microvascular disease of type 2
diabetes.
4.1. Limitations. We graded the severity of retinal involve-
mentbyasimpliﬁedscorethathasbeenvalidatedinprevious
studies by our [5] and other [6, 13–15] groups and has
been recently used in other large-scale, prospective, and
randomizedclinicaltrials[16].Comparedtoamorecomplex
score implemented to grade retinal involvement in people
with diabetes [17], this approach discriminates only two
stages (pre-proliferative and proliferative) of retinopathy.
Thus changes in one or more grades within the same pre-
proliferative or proliferative stage could not be captured by
this approach. This reduced the sensitivity and precision of
the assessment and, secondarily, the power of the analyses
but did not introduce a systematic bias since the same
limitation was applied to the same extent to each considered
patient group. On the other hand, compared to more
complex approaches, the criteria we used to grade retinal
involvement in our present study more closely reﬂect the
criteria normally used in every-day clinical practice, which
enhances the generalizability of our present ﬁndings to the
average population of patients with type 2 diabetes.
Regressionofretinopathywasthemainoutcomevariable
of a substudy ancillary to BENEDICT phase A. Thus,
the substudy was not powered ap r i o r ion the basis of
an expected treatment eﬀect on the regression of retinal
involvement but rather aimed at including all BENEDICT
patients with available funduscopy evaluation at baseline.
However, a posteriori evaluations showed that, due to the
strong treatment eﬀect of trandolapril, the probability of a
false positive ﬁnding was less than two percent.
Finally, analysis was restricted to patients referred to two
of the nine Centers involved in the BENEDICT trial. This
was because of the logistic possibility for these Centers to
refer randomized patients to the Unit of Ophthalmology
where funduscopy evaluations were performed (these three
Institutions were in the same urban area). However, since
randomization to diﬀerent treatment arms was balanced
within each Center, this did not introduce any appreciable
bias. This is consistent with the evidence that patient
distribution was balanced, and baseline characteristics were
similar among diﬀerent treatment groups.
5. Conclusions
The present study, along with the recently published
DIRECT-Protect 2 trial, provided the evidence that dia-
betic retinopathy can regress. This may have important
clinical implications since regression of retinal damage may
limit the risk of visual loss in the long term. Moreover,
microvascular complications of diabetes, such as nephropa-
thy and retinopathy, may reﬂect coronary ischemic disease
and predict cardiovascular morbidity and mortality [18].
Conceivably, as already reported for regression of renal
disease, regression of retinopathy might also predict reduced
cardiovascular risk in the long-term.
Our present data showed that RAS inhibition with
the ACEi trandolapril, unlike calcium channel blockade by
verapamil, had a beneﬁcial eﬀect that exceeded the beneﬁt
expected from the reduction in arterial BP and blood
glucose observed during the study. Importantly, the ACEi
trandolapril, compared to the ARB candesartan tested in the
DIRECT-Protect 2 trial, has the advantage of remarkably
lower treatment costs (US$ 1.10 versus 2.60, $ 0.24 versus
0.58, or Euro 0.49 versus 0.94 for one day therapy with
trandolapril 2mg or candesartan 32mg, resp.). Costs can
be further reduced by using the generic compound that
is currently available in most countries. Improving cost-
eﬀectiveness of intervention programs at population level
would have major implications, as diabetic retinopathy is
a leading cause of visual impairment worldwide [1], and
its incidence is expected to further increase along with the
forecasted epidemic of diabetes, in particular in developing
countries [19].
Considering the tremendous burden of diabetes and of
itschroniccomplications,theseﬁndingsmayhaveimportant
clinical and social implications for patients, physicians, and
other health care providers.
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